How Have the Numbers Shaped Up for Humanigen (NASDAQ:HGEN)

Earnings results for Humanigen (NASDAQ:HGEN)

Humanigen, Inc. is estimated to report earnings on 08/13/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.46. The reported EPS for the same quarter last year was $-0.8.

Humanigen last announced its quarterly earnings results on May 13th, 2021. The reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by $0.61. The firm had revenue of $0.49 million for the quarter. Humanigen has generated ($2.42) earnings per share over the last year (($3.39) diluted earnings per share). Earnings for Humanigen are expected to grow by 30.43% in the coming year, from $3.45 to $4.50 per share. Humanigen has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Friday, August 13th, 2021 based off prior year’s report dates.

Analyst Opinion on Humanigen (NASDAQ:HGEN)

8 Wall Street analysts have issued ratings and price targets for Humanigen in the last 12 months. Their average twelve-month price target is $30.88, predicting that the stock has a possible upside of 80.98%. The high price target for HGEN is $40.00 and the low price target for HGEN is $21.00. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Humanigen has received a consensus rating of Buy. The company’s average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings. According to analysts’ consensus price target of $30.88, Humanigen has a forecasted upside of 81.0% from its current price of $17.06. Humanigen has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Dividend Strength: Humanigen (NASDAQ:HGEN)

Humanigen does not currently pay a dividend. Humanigen does not have a long track record of dividend growth.

Insiders buying/selling: Humanigen (NASDAQ:HGEN)

In the past three months, Humanigen insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $40,144,010.00 in company stock. 27.30% of the stock of Humanigen is held by insiders. A high percentage of insider ownership can be a sign of company health. Only 38.45% of the stock of Humanigen is held by institutions.

Earnings and Valuation of Humanigen (NASDAQ:HGEN

Earnings for Humanigen are expected to grow by 30.43% in the coming year, from $3.45 to $4.50 per share. The P/E ratio of Humanigen is -5.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Humanigen is -5.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Humanigen has a P/B Ratio of 19.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here